How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?

Key Takeaways ABBV's neuroscience franchise is expected to generate $2.5 billion in Q2, up 15% year over year. Growth likely driven by Botox Therapeutic, Vraylar and market share gains for Qulipta and Ubrelvy. Newly launched Vyalev may contribute modest U.S. sales, with most revenues from international markets.AbbVie (ABBV) holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic and depression drug Vraylar. Over the years, the company has ...